ENLV (ENLV) Stock Price & Analysis
ENLV (ENLV) fell 3.67% to USD 4.2 as of July 25, 2026 at 08:05 UTC, according to Nexqual real-time market data.
ENLV last closed at USD 4.36; the session ranged USD 4.08–4.47 on volume of 106,527 shares. Market capitalization is $70.69M, with a 52-week range of USD 4.08–31.5 (NCM). Source: Nexqual, July 25, 2026 at 08:05 UTC.
Key Statistics (as of July 25, 2026 at 08:05 UTC)
| Price | USD 4.2 |
|---|---|
| Change | ▼ 3.67% (down) |
| Previous Close | USD 4.36 |
| Open | USD 4.36 |
| Day Range | USD 4.08 – 4.47 |
| 52-Week Range | USD 4.08 – 31.5 |
| Volume | 106,527 shares |
| Market Cap | $70.69M |
| Exchange | NCM |
Technical Analysis (ENLV)
Nexqual's technical model rates ENLV "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 08:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 10.67 (oversold) |
| vs SMA50 | Below (USD 8.95) |
| MACD | -1.42 (negative) |
Analyst Ratings (ENLV)
Wall Street analysts rate ENLV "None" based on 1 analysts, with a mean price target of USD 300 (range USD 300–300), per Nexqual as of July 25, 2026 at 08:05 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 300 |
| High Target | USD 300 |
| Low Target | USD 300 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (ENLV)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -1.41 vs est -0.45 ▼ miss |
| 2025-09-30 | USD -1.35 vs est -1.8 ▲ beat |
| 2025-06-30 | USD -1.2 vs est -2.4 ▲ beat |
| 2025-03-31 | USD -2.25 vs est -2.4 ▲ beat |
Source: Nexqual, July 25, 2026 at 08:05 UTC.
Financials & Fundamentals (ENLV)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | +126.17% |
| Debt / Equity | 0.03 |
| Current Ratio | 193.24 |
| Total Cash | $5.75M |
| Total Debt | $641,000 |
| Free Cash Flow | $-1.74B |
Source: Nexqual, July 25, 2026 at 08:05 UTC.
Financial Health Score (ENLV)
Nexqual rates ENLV's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 08:05 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $6M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$10M |
| Efficiency | Strong — ROE 126%, ROA -0.8% |
Ownership (ENLV)
| Insider Ownership | +81.40% |
|---|---|
| Institutional Ownership | +1.44% |
| Shares Outstanding | 16.83M |
| Float | 3.85M |
| Short % of Float | +0.16% |
Source: Nexqual, July 25, 2026 at 08:05 UTC.
Leadership (ENLV)
ENLV is led by Oren Hershkovitz (age 48), Chief Executive Officer, per Nexqual as of July 25, 2026 at 08:05 UTC.
| Chief Executive Officer | Oren Hershkovitz (age 48) |
|---|---|
| Executive Chairman | Shai Novik (age 59) |
| Chief Financial Officer | Shachar Shlosberger (age 48) |
| Senior Director of Operations | Veronique Amor-Baroukh |
| Director of Human Resources | Sigal Arad |
Major Backers & Investors (ENLV)
Notable institutional backers of ENLV include ARK Invest, Diametric Capital, Lp, according to Nexqual as of July 25, 2026 at 08:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 1.19% |
| Diametric Capital, Lp | 0.59% |
Source: Nexqual, July 25, 2026 at 08:05 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KMDA | Kamada Ltd. | USD 7.06 | ▲ 0.71% |
| EVGN | Evogene Ltd. | USD 0.54 | ▲ 0.46% |
| ENTX | Entera Bio Ltd. | USD 2.05 | ▲ 0.99% |
| RDHL | Redhill Biopharma Ltd. | USD 0.63 | ▼ 7.55% |
| EDSA | Edesa Biotech, Inc. | USD 5.25 | ▼ 7.57% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 08:05 UTC. This page is informational and not investment advice.